RXRX
Recursion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.63
+5.52%Aug 6, 2026, 10:30 UTC
Roche is using Recursion's AI platform to identify new targets for brain diseases.
Source:Aug 5, 2026, 10:30 UTC
Genentech exercised its option to advance the first neuroscience target from the Recursion collaboration into a joint early discovery program.
Source:Aug 5, 2026, 10:30 UTC
The FDA cleared the Investigational New Drug application for REC-7735, a PI3Kα H1047R inhibitor, allowing Recursion to proceed with a Phase 1/2 trial.
Source:Aug 5, 2026, 00:00 UTC
Recursion Pharmaceuticals reported its Q2 2026 financial results, with total revenue of $7.7 million, a net loss of $131.0 million, and diluted EPS of -$0.25.